In the second quarter it paid to be a leading obesity company. As for Covid, not so much.
Nash data are due for Terns and Inventiva, as Marinus aims to expand its rare disease offering.
Leqembi seeks full approval, while Takeda hopes for a dengue green light and Verrica looks to break its streak of bad luck.
Key catalysts lie ahead for Amgen, Argenx, Point Biopharma and Novo Nordisk.
J&J moves FcRn towards a big new therapy area, while Bristol, Merck, Astrazeneca and Daiichi Sankyo await important oncology catalysts.
SRP-9001 heads for its month of regulatory probing, as vaccines from GSK and Pfizer, and Genmab and Abbvie’s bispecific, await FDA approval decisions.